Newsletter Tool

Today's Rundown

Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit
BD’s medical segment president Mas set to retire after 30 years
California auditors outline rampant fraud endangering LA County hospice patients
UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab
Synchron’s brain-computer interface implant deemed safe after 1 year in ALS patients
HRSA calls for Boehringer Ingelheim to be fined over 340B contract pharmacy restrictions
Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon
Bayer sheds some sites in €2B push to expand next-gen manufacturing capabilities
AHA launches Health Equity Roadmap, an interactive program for members to build out their equity efforts
Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studies
Fresenius Kabi picks up smart infusion pump developer Ivenix plus a stake in biosimilar maker mAbxience
Feds probe ring of counterfeit HIV meds targeting Gilead, GlaxoSmithKline and Johnson & Johnson: report
2 gene editing biotechs team up to improve on delivery with $45 upfront

Featured Story

Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit

By Ben Adams

It wasn’t supposed to be this way. Zealand Pharma should be in the honeymoon glow of its first drug launch with an approval less than a year ago. Instead, it's losing its CEO and shedding 90% of its U.S. workforce.

BD’s medical segment president Mas set to retire after 30 years

By Andrea Park

After spending nearly half his life and the majority of his career with the company, Alberto Mas has made plans to retire from BD later this year—just shy of his 30th anniversary there.

California auditors outline rampant fraud endangering LA County hospice patients

By Dave Muoio

Among the evidence of a "large and organized effort to defraud the Medicare and Medi-Cal" hospice programs cited by auditors was a single building containing over 150 licensed hospice and home health agencies.

UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab

By Annalee Armstrong

With CytoDyn's lead drug on FDA clinical hold, the troubled biotech will go searching for partners to rescue key programs and keep afloat. Meanwhile, the board is actively searching for a new CEO to replace Nader Pourhassan, Ph.D., who was ousted in January.

Synchron’s brain-computer interface implant deemed safe after 1 year in ALS patients

By Andrea Park

New results from Synchron’s first human study of its brain-computer interface system found that one year after the device’s placement, none of the four participants had experienced any adverse events that led to disability or death.

HRSA calls for Boehringer Ingelheim to be fined over 340B contract pharmacy restrictions

By Robert King

HRSA is pushing for Boehringer Ingelheim to be fined for its decision to cut off sales of 340B-discounted products to contract pharmacies.

Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon

By Max Bayer

Eikon Therapeutics continues to reunite former Merck colleagues, this time adding former CEO Ken Frazier to its board. Frazier's appointment is the third former Merck colleague to join this year after the company's former R&D president Roger Perlmutter was tapped as CEO in May 2021.

Bayer sheds some sites in €2B push to expand next-gen manufacturing capabilities

By Joseph Keenan

German pharma giant Bayer plans to spend 2 billion euros ($2.2 billion) over the next three years to upgrade its manufacturing and supply chain capabilities as it dives deeper into cell and gene therapies. As part of the effort, the company is selling certain sites to outside partners.

PM Tracker

Featured Story

Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit

Top Stories

BD’s medical segment president Mas set to retire after 30 years

California auditors outline rampant fraud endangering LA County hospice patients

UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab

Synchron’s brain-computer interface implant deemed safe after 1 year in ALS patients

HRSA calls for Boehringer Ingelheim to be fined over 340B contract pharmacy restrictions

Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon

Bayer sheds some sites in €2B push to expand next-gen manufacturing capabilities

AHA launches Health Equity Roadmap, an interactive program for members to build out their equity efforts

Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studies

Fresenius Kabi picks up smart infusion pump developer Ivenix plus a stake in biosimilar maker mAbxience

Feds probe ring of counterfeit HIV meds targeting Gilead, GlaxoSmithKline and Johnson & Johnson: report

2 gene editing biotechs team up to improve on delivery with $45 upfront